Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Fortress Biotech Inc.
Headquarters: New York, NY, United States of America
Website: http://www.fortressbiotech.com...
Year Founded: 2006
Status: Public
Industry Sector: HealthTechnology
CEO: Lindsay Allan Rosenwald, MD
Number Of Employees: 101
Enterprise Value: $36,407,276
PE Ratio: -0.48
Exchange/Ticker 1: NASDAQ:FBIO
Exchange/Ticker 2: N/A
Latest Market Cap: $42,233,300
BioCentury | Mar 10, 2025
Deals
Sun takes shine to Checkpoint in $355M buyout: Deals Report
Plus: Jazz acquires Chimerix for 72% premium, and J&J does not exercise HexaBody Genmab option, Myokardia ends partnership with Fulcrum
BioCentury | Oct 4, 2022
Management Tracks
Sause named CEO of Roche Diagnostics
Plus Kranzler becomes CEO of Urica, and updates from Pharus, Celularity, Cerevance and more
BioCentury | Sep 12, 2022
Management Tracks
Biden names Wegrzyn to lead ARPA-H
Plus bluebird’s Cole resigns as CFO, and updates from Cellics, Scorpion, Day One and more
BioCentury | Jul 23, 2022
Management Tracks
Marti leaving Novartis Oncology legal team
Plus Versant promotes Rizzuto and updates from Fortress and ITM
BioCentury | Oct 19, 2021
Management Tracks
Insilico rounds out C-suite as it readies for clinic, U.S. growth
Addition of veteran dealmaker Michelle Chen completes AI company’s executive team
BioCentury | Sep 29, 2021
Deals
AZ’s exercise of Caelum option brings in amyloidosis therapy
Pharma pays $150M for single-asset Caelum, gaining mAb for AL amyloidosis
BioCentury | Sep 28, 2021
Management Tracks
Peng joins Denali as chief commercial officer
Plus: Twist, Vaxart, Insilico, Gilde, Panakes and more
BioCentury | May 20, 2021
Deals
Neuro deal flow: pharmas pinning hopes on new modalities, delivery technologies
The last three years of deals prioritize new modalities against known targets and CNS entry over discovery of new targets
BioCentury | Feb 23, 2021
Management Tracks
Genmab names Ahmadi CMO, head of experimental medicines; plus moves at Wugen and Aevitas
Genmab A/S (CSE:GMAB; NASDAQ:GMAB) promoted Tahamtan Ahmadi from SVP, head of oncology to EVP and CMO, head of experimental medicines, a newly created position. Before joining Genmab in 2017, Ahmadi
BioCentury | Jan 6, 2021
Management Tracks
Lin leaving Nektar as CMO; plus HKEX’s Tai named interim CEO, PureTech, Patient Square Capital, Novacyt and more
Wei Lin is leaving Nektar Therapeutics (NASDAQ:NKTR) as CMO to pursue another opportunity. Brian Kotzin, who is SVP, clinical development and head of immunology at the company, will serve as
Items per page:
1 - 10 of 50